French Innovative Leukemia Organisation
Clinical trials sponsored by French Innovative Leukemia Organisation, explained in plain language.
-
New CLL combo aims for Long-Term remission without lifelong pills
Disease control Not yet recruitingThis phase II trial tests a new drug called pirtobrutinib combined with a short course of chemotherapy in 82 fit patients with untreated CLL. The goal is to achieve deep remission with undetectable cancer cells in the blood at 24 months. The treatment lasts only 15 months, aiming…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo aims to stop leukemia return in older patients
Disease control Not yet recruitingThis study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from coming back in people over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills d…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo therapy targets blood cancer relapse
Disease control Not yet recruitingThis study tests a combination of two oral drugs, zanubrutinib and BGB-11417, in adults with Waldenström macroglobulinemia who have already received at least one prior treatment. The goal is to see if the combination can shrink or control the cancer better than current options. P…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC